ATP Clinical Research, Costa Mesa, CA, USA.
CNS Spectr. 2023 Oct;28(5):521-525. doi: 10.1017/S1092852923002213. Epub 2023 Mar 27.
Major depressive disorder (MDD) is a leading contributor to disability worldwide and is associated with increased morbidity and mortality. Current pharmacologic treatment options may be ineffective for some patients and can pose several limitations and challenges, including suboptimal response and slow onset of action. Many of these therapies can take 6 to 8 weeks for patients to achieve response and 12 weeks or longer to demonstrate full clinical benefit. Delays in depressive symptom resolution are associated with poor symptomatic and functional outcomes, decreased quality of life, and increased burden on the healthcare system. Achieving response and remission of symptoms soon after diagnosis and treatment is associated with lower rates of relapse and a greater likelihood of functional recovery. An unmet need exists for innovative treatments that offer rapid and sustained effects. This editorial discusses the benefits of rapid improvement in depressive symptoms with available and investigational agents for patients with MDD.
重度抑郁症（MDD）是全球导致残疾的主要原因之一，与发病率和死亡率增加有关。目前的药物治疗选择可能对某些患者无效，并且可能存在多种局限性和挑战，包括反应不佳和起效缓慢。这些疗法中的许多药物需要 6 到 8 周的时间才能使患者产生反应，需要 12 周或更长时间才能显示出完全的临床疗效。抑郁症状缓解的延迟与较差的症状和功能结果、生活质量下降以及医疗保健系统负担增加有关。在诊断和治疗后尽快获得症状缓解和缓解与较低的复发率和更高的功能恢复可能性相关。对于提供快速和持续效果的创新治疗方法存在未满足的需求。这篇社论讨论了 MDD 患者使用现有和研究中的药物迅速改善抑郁症状的好处。
